Inactive Instrument

Dicerna Pharmaceuticals, Inc.

Equities

DRNA

US2530311081

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Dicerna Pharmaceuticals Coverage Dropped by Chardan After Novo Nordisk Closes Acquisition MT
Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo Nordisk MT
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from S&P Global BMI Index CI
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from S&P TMI Index CI
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from S&P Biotechnology Select Industry Index CI
Novo Nordisk Completes Dicerna Pharmaceuticals Acquisition MT
Novo Nordisk Closes on $3.3 Billion Acquisition of Dicerna Pharmaceuticals MT
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from NASDAQ Composite Index CI
Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of remaining 97% stake in Dicerna Pharmaceuticals, Inc.. CI
Dicerna Pharmaceuticals, Inc.(NasdaqGS:DRNA) dropped from NASDAQ Biotechnology Index CI
Chardan Downgrades Dicerna Pharmaceuticals to Neutral Rating From Buy on Proposed Acquisition by Novo Nordisk, Adjusts PT to $38.25 From $28 MT
Chardan Downgrades Dicerna Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $38.25 From $28 on Pending Acquisition MT
Insider Sell: Dicerna Pharmaceuticals MT
Stifel Downgrades Dicerna Pharmaceuticals to Hold From Buy, Adjusts Price Target to $38 From $35 MT
Alnylam Pharmaceuticals Upgraded to Outperform From Sector Perform by RBC After R&D Day, Price Target Raised to $225 From $144 MT
North American Morning Briefing : Stock Futures -3- DJ
B. Riley Downgrades Dicerna Pharmaceuticals to Neutral from Buy After Announcing $3.3 Billion Sale to Novo Nordisk, Lifts PT to $38.25 from $35 MT
RBC Downgrades Dicerna Pharmaceuticals to Sector Perform From Outperform, Lifts PT to $38.25 From $30 on Novo Nordisk Deal; Speculative Risk Qualifier Kept MT
HC Wainwright Downgrades Dicerna Pharmaceuticals to Neutral From Buy, Adjusts PT to $38.35 From $32 MT
Health Care Stocks Ending Little Changed in Quiet Trading MT
Health Care Stocks Weakening This Afternoon MT
Sector Update: Health Care MT
Dicerna Shares Soar on Takeover by Novo Nordisk DJ
Wall Street Set for Positive Open as Upbeat Nvidia Earnings Buoy Sentiment MT
Health Care Stocks Edge Higher Premarket Thursday MT
Chart Dicerna Pharmaceuticals, Inc.
More charts
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. The Company's GalXC RNAi technology Platform consists of its liver-targeted GalXC technology and GalXC-Plus technology for tissues outside the liver. The Company's product line includes nedosiran, RG6346, belcesiran, and DCR-AUD. Its lead product candiadate nedosiran is a RNAi drug candidate developed for the treatment of hyperoxaluria (PH). The RG6346 for the treatment of chronic hepatitis B virus (HBV) infection. The belcesiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (AATLD). The DCR-AUD for the treatment of alcohol use disorder (AUD).
More about the company
  1. Stock
  2. Equities
  3. Stock Dicerna Pharmaceuticals, Inc. - Nasdaq
  4. News Dicerna Pharmaceuticals, Inc.
  5. Earnings Flash (DRNA) DICERNA PHARMACEUTICALS Posts Q3 Revenue $63M, vs. Street Est of $43.8M